ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00428844
Recruitment Status : Completed
First Posted : January 30, 2007
Results First Posted : June 14, 2011
Last Update Posted : January 31, 2018
Sponsor:
Information provided by (Responsible Party):
Cubist Pharmaceuticals LLC

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Osteomyelitis
Interventions: Drug: daptomycin
Drug: vancomycin
Drug: teicoplanin
Drug: nafcillin
Drug: oxacillin
Drug: flucloxacillin

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Daptomycin 6 mg/kg Daptomycin (6 mg/kg every 24 hours [q24h]) as a 30 minute intravenous (IV) infusion for 6 weeks (± one week).
Daptomycin 8 mg/kg Daptomycin (8 mg/kg q24h) as a 30 minute IV infusion for 6 weeks (± one week).
Comparator Vancomycin was administered at 1 gram (gm)every 12 hours (q12h) as a 60-minute infusion and teicoplanin was administered 6 mg/kg q24h as a 30-minute infusion also for 6 weeks (±1 week). Semi-synthetic penicillin (nafcillin, oxacillin, or flucloxacillin) was administered according to standard of care for 6 weeks (±1 week).

Participant Flow for 2 periods

 Period 1:   Completed Study Drug Treatment
    Daptomycin 6 mg/kg   Daptomycin 8 mg/kg   Comparator
STARTED   25   24   26 
Received First Dose   25   24   25 
COMPLETED   23   18   19 
NOT COMPLETED   2   6   7 
Adverse Event                2                4                4 
Protocol Violation                0                1                1 
Withdrawal by Subject                0                1                1 
Randomized Not Treated                0                0                1 

Period 2:   Completed Test of Cure (TOC) Visit
    Daptomycin 6 mg/kg   Daptomycin 8 mg/kg   Comparator
STARTED   23   18   19 
COMPLETED   20   16   17 
NOT COMPLETED   3   2   2 
Adverse Event                0                1                1 
Protocol Violation                0                0                1 
Withdrawal by Subject                1                0                0 
Lack of Efficacy                2                0                0 
Microbiologic failure                0                1                0 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Daptomycin 6 mg/kg Daptomycin (6 mg/kg q24h) as a 30-minute IV infusion for 6 weeks (±1 week).
Daptomycin 8 mg/kg Daptomycin (8 mg/kg q24h) as a 30-minute IV infusion for 6 weeks (±1 week).
Comparator Vancomycin was administered at 1 gm q12h as a 60-minute infusion and teicoplanin was administered 6 mg/kg q24h as a 30-minute infusion also for 6 weeks (±1 week). Semi-synthetic penicillin (nafcillin, oxacillin, or flucloxacillin) was administered according to standard of care for 6 weeks (±1 week).
Total Total of all reporting groups

Baseline Measures
   Daptomycin 6 mg/kg   Daptomycin 8 mg/kg   Comparator   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 25   24   25   74 
Age [1] 
[Units: Participants]
Count of Participants 		       
<=18 years      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      10  40.0%      14  58.3%      15  60.0%      39  52.7% 
>=65 years      15  60.0%      10  41.7%      10  40.0%      35  47.3% 
[1] Safety/Intent to Treat Population (1 patient included in the Overall Number of Baseline Participants was randomized to comparator but not treated)
Sex: Female, Male [1] 
[Units: Participants]
Count of Participants 		       
Female      14  56.0%      10  41.7%      11  44.0%      35  47.3% 
Male      11  44.0%      14  58.3%      14  56.0%      39  52.7% 
[1] Safety/Intent to Treat Population (1 patient included in the Overall Number of Baseline Participants was randomized to comparator but not treated)


  Outcome Measures

1.  Primary:   Any Creatine Phosphokinase (CPK) Elevation > 500 Units Per Liter (U/L)   [ Time Frame: From the 3rd day of therapy to 1 week post last dose (approximately week 7) ]
  Show Outcome Measure 1

2.  Secondary:   Safety - Notable Laboratory Abnormalities   [ Time Frame: From the 1st day of therapy to maximum of 23 weeks post last dose (up to maximum of week 30) ]
  Show Outcome Measure 2

3.  Secondary:   Overall Clinical Outcome   [ Time Frame: Approximately 6 weeks post last dose (approximately week 12) ]
  Show Outcome Measure 3

4.  Secondary:   Microbiological Response   [ Time Frame: Approximately 6 weeks post last dose (approximately week 12) ]
  Show Outcome Measure 4

5.  Secondary:   Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax)   [ Time Frame: Day 4 (steady state) ]
  Show Outcome Measure 5

6.  Secondary:   Pharmacokinetic Parameter: Area Under the Concentration-time Curve During a Dosing Interval at Steady State (AUCss)   [ Time Frame: Day 4 (steady state) ]
  Show Outcome Measure 6


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Ed Campanaro, VP Clinical Operations
Organization: Cubist Pharmaceuticals, Inc.
phone: 781-860-8318
e-mail: ed.campanaro@cubist.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):


Responsible Party: Cubist Pharmaceuticals LLC
ClinicalTrials.gov Identifier: NCT00428844     History of Changes
Other Study ID Numbers: 3009-016
DAP-OST-06-02 ( Other Identifier: Cubist Study Number )
First Submitted: January 26, 2007
First Posted: January 30, 2007
Results First Submitted: March 16, 2011
Results First Posted: June 14, 2011
Last Update Posted: January 31, 2018